Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Moyamoya in a Child Treated With Interferon for Recurrent Osteosarcoma JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY Buchbinder, D., Steinberg, G., Linetsky, M., Casillas, J. 2010; 32 (6): 476-478

Abstract

Moyamoya is a cerebral vasculopathy of unknown etiology rarely described as a late effect after the treatment of childhood cancer. We describe a 12-year-old female who developed moyamoya after the completion of systemic chemotherapy, surgery, and adjuvant interferon alpha for osteosarcoma with pulmonary metastases. Given the importance of characterizing late effects after the treatment of childhood cancer, the potential role of interferon alpha in the development of moyamoya is discussed.

View details for DOI 10.1097/MPH.0b013e3181e5e1db

View details for Web of Science ID 000280666100007

View details for PubMedID 20562650